Drug-Eluting Balloons versus Second-Generation Drug-Eluting Stents for Treating In-Stent Restenosis in Coronary Heart Disease after PCI: A Meta-Analysis

Table 3

Baseline angiographic characteristics.

Study	Pre-MLD		Pre-DS%		Lesion length (mm)		Post-MLD		Post-DS%
	DEB	DES	DEB	DES	DEB	DES	DEB	DES	DEB	DES
Adriaenssens [15]	0.98 ± 0.60	0.57 ± 0.37	67.7 ± 18.4	79.4 ± 13.5	NR	NR	2.13 ± 0.45	2.12 ± 0.51	26.6 ± 13	25.9 ± 16.8
Alfonso et al. [16]	1.02 ± 0.40	0.93 ± 0.4	61 ± 14	65 ± 13	13.7 ± 7	13.8 ± 6	2.16 ± 0.5	2.38 ± 0.5	19 ± 11	11 ± 11
Almalla et al. [17]	0.57 ± 0.30	0.51 ± 0.41	NR	NR	9 ± 5.2	12.3 ± 11	2.42 ± 0.36	2.5 ± 0.5	NR	NR
Kubo et al. [19]	0.96 ± 0.45	0.80 ± 0.47	67 ± 14.9	72.2 ± 15.1	16.7 ± 12.9	15.7 ± 8.2	2.02 ± 0.4 4	2.56 ± 0.54	31.8 ± 10.3	16.2 ± 7.4
Alfonso et al. [20]	0.79 ± 0.40	0.75 ± 0.40	69 ± 17	72 ± 15	10.4 ± 5.6	10.7 ± 5.4	2.1 ± 0.4	2.22 ± 0.5	18 ± 10	13 ± 11
Kang et al. [21]	0.80 ± 0.40	0.80 ± 0.60	71.7 ± 5.2	74.6 ± 9.2	19.5 ± 8.9	21.3 ± 11.8	2.2 ± 0.4	2.7 ± 0.4	20.6 ± 11.9	13.6 ± 10.5
Kawamoto et al. [23]	0.74 ± 0.49	0.66 ± 0.43	74.8 ± 15.8	81.2 ± 14.4	18.7 ± 14.6	16.1 ± 9.6	2.34 ± 0.54	2.65 ± 0.48	18.2 ± 8.6	13.8 ± 7.6
Pleva et al. [24]	0.92 ± 0.45	0.79 ± 0.48	71.8 ± 13.9	78 ± 13.4	NR	NR	2.18 ± 0.39	2.51 ± 0.38	19.5 ± 7.4	16.3 ± 8.9

MLD: minimum luminal diameter; DS%: percent diameter stenosis; LLL: late lumen loss.